Stock Events

Stock Events

Galmed Pharmaceuticals 

$0.67
26
-$0.04-6.28% Monday 21:00

Statistics

Day High
0.71
Day Low
0.66
52W High
3.5
52W Low
0.66
Volume
90,628
Avg. Volume
2,130,042
Mkt Cap
3.65M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

1AprExpected
Q2 2024
Q3 2024
Q1 2025
Q1 2025
Q2 2025
Q3 2025
Next
-1.94
-1.4
-0.87
-0.33
Expected EPS
-0.51
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
0Revenue
-15.03MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow GLMD. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Madrigal Pharmaceuticals
MDGL
Mkt Cap9.34B
Madrigal Pharmaceuticals is developing treatments for NASH, directly competing with Galmed's pipeline.
Viking Therapeutics
VKTX
Mkt Cap4.3B
Viking Therapeutics is working on treatments for metabolic and endocrine disorders, including NASH, making it a direct competitor.
Genfit
GNFT
Mkt Cap211.72M
Genfit SA focuses on the discovery and development of drug candidates to treat liver diseases such as NASH, competing in the same space as Galmed.
Gilead Sciences
GILD
Mkt Cap148.78B
Gilead Sciences has a strong pipeline in liver disease treatments, including NASH, positioning it as a competitor.
Agios Pharmaceuticals
AGIO
Mkt Cap2.52B
Agios Pharmaceuticals, though primarily focused on cancer, has expanded into metabolic disorders, potentially competing in the NASH space.
Novartis
NVS
Mkt Cap237.61B
Novartis AG, a large pharmaceutical company, has interests in developing treatments for liver diseases, including NASH, making it a competitor.
Abbvie
ABBV
Mkt Cap385.18B
AbbVie Inc. has a diverse portfolio that includes research in liver diseases, potentially putting it in competition with Galmed.
Pfizer
PFE
Mkt Cap140.15B
Pfizer Inc. is involved in developing treatments for a wide range of conditions, including liver diseases, which could compete with Galmed's products.
Merck
MRK
Mkt Cap214.76B
Merck & Co., Inc. has a broad research portfolio that could include NASH treatments, positioning it as a potential competitor.

About

Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. It has a research agreement with Gannex Pharma Co., Ltd. to develop a combination therapy of ASC41 (THR-beta agonist) and Aramchol (SCD 1 inhibitor) for the treatment of NASH; a research and development collaboration agreement with MyBiotics Pharma Ltd. to identify the selected microbiome repertoire associated with the response to Aramchol; and a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Tel Aviv, Israel.
Show more...
CEO
Mr. Allen Baharaff
Employees
3
Country
IL
ISIN
IL0011313900

Listings

F
DE
GPH.F
XNAS
US
GLMD
BOATS
BOATS
GLMD.BOATS

0 Comments

Share your thoughts

FAQ

What is Galmed Pharmaceuticals stock price today?▼
The current price of GLMD is $0.67 USD — it has decreased by -6.28% in the past 24 hours. Watch Galmed Pharmaceuticals stock price performance more closely on the chart.
What is Galmed Pharmaceuticals stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Galmed Pharmaceuticals stocks are traded under the ticker GLMD.
Is Galmed Pharmaceuticals stock price growing?▼
GLMD stock has fallen by -21.25% compared to the previous week, the month change is a -19.14% fall, over the last year Galmed Pharmaceuticals has showed a -75.36% decrease.
What is Galmed Pharmaceuticals market cap?▼
Today Galmed Pharmaceuticals has the market capitalization of 3.65M
When is the next Galmed Pharmaceuticals earnings date?▼
Galmed Pharmaceuticals is going to release the next earnings report on April 01, 2026.
What were Galmed Pharmaceuticals earnings last quarter?▼
GLMD earnings for the last quarter are -0.33 USD per share, whereas the estimation was -0.54 USD resulting in a +38.89% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Galmed Pharmaceuticals revenue for the last year?▼
Galmed Pharmaceuticals revenue for the last year amounts to 0 USD.
What is Galmed Pharmaceuticals net income for the last year?▼
GLMD net income for the last year is -15.03M USD.
How many employees does Galmed Pharmaceuticals have?▼
As of February 03, 2026, the company has 3 employees.
In which sector is Galmed Pharmaceuticals located?▼
Galmed Pharmaceuticals operates in the Health Care sector.
When did Galmed Pharmaceuticals complete a stock split?▼
The last stock split for Galmed Pharmaceuticals was on August 30, 2024 with a ratio of 1:12.
Where is Galmed Pharmaceuticals headquartered?▼
Galmed Pharmaceuticals is headquartered in Ramat Gan, IL.